Diagnostic Assays

For more information on UTMDACC technologies, please contact the Office of Technology Commercialization (713-745-9604).  Please indicate the technology number (MDA#) in your correspondence.

MDA09-074
A Nine Gene Predictor of Therapy Response in Adult Philadelphia-chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Please contact the office for more information on this technology.

MDA09-067
Novel Gene Set Identification and Pathway Specific Survival Patterns Using Gene Expression Profiling of Human Glioblastoma: A Study Based on TCGA Data Analysis
Please contact the office for more information on this technology.

MDA09-054
Prognostic Relevance of Dicer and Drosha
Please contact the office for more information on this technology.

MDA09-026
Marker-based Prognostic Risk Score for Esophagealgastric Cancer
Please contact the office for more information on this technology.

MDA09-005
A MicroRNA Signature to Predict Prognosis in Human Heart Failure
Please contact the office for more information on this technology.

MDA08-153
An Improved Classification Scheme for Breast Cancer Based on Disease Dynamics
Please contact the office for more information on this technology.

MDA08-100
Biomarker Signature to Treat Esphogeal Cancer
Please contact the office for more information on this technology.

MDA08-074
Diagnostic Testing for the Presence of Cancer by Detecting p-STAT-3 in Perpherial Blood
Please contact the office for more information on this technology.

MDA08-054
SNPs on Chromosome 15 Predicting Risk for Lung Cancer
Please contact the office for more information on this technology.

MDA07-125
Non-invasive Detection of Bladder Cancer by Fluorescence in situ Hybridization of Aurora A
Please contact the office for more information on this technology.

MDA07-083
Antibody Dependent Micro Beads
Please contact the office for more information on this technology.

MDA07-064
MicroRNA 1960a and micro RNA 196b (miR-196a and miR-196b) are Candidate microRNA Regulators of Annexin A1(ANXA1) Esophageal and Breast Cancers
Please contact the office for more information on this technology.

MDA06-122
An Assay to Predict Recurrence Risk in Breast Cancer using the Novel Tumor Suppressor DEAR1
Please contact the office for more information on this technology.

MDA06-105
Methods for Assessing Cancer Susceptibility to Carcinogens in Tobacco Products
WO2007/146883

MDA06-103
Developing a highly sensitive assay for Circulating Tumor cells using patented biomarkers
Please contact the office for more information on this technology.

MDA06-070
A Multigene Assay to Predict Outcome in Patients With Glioblastoma
WO 2008/109423

MDA06-024
Gene Expression Profiling of Localized Esophageal Carcinomas: Association with Pathologic Response to Preoperative Chemoradiation
WO2008/073878

MDA05-132
Development of a Blood-Based Test Allowing Screening for and Early Diagnosis of Ovarian Cancer: Detection of Anti-(poly)-N-acetyllactorsamine Specific Antibodies from Human Sera Using Defined Printed Glycan Array.
US-2007-0265170-A1

MDA05-057
Assessment of Genetic Susceptibility to Develop Non-Small Cell Lung Cancer Via an Array of Multi-Probe FISH tests in Sputum Based on Discovery of a Pluipotent Stem Cell that Gives Rise to Both Epithelial Carcinoma and Neutrophiles that Bear Identical
WO 2007/087612
US-2007-0218480-A1

MDA05-021
Development of Blood-based Test Allowing Diagnosis of Neoplasia Status: Detection of Neoplasia-specific Clusters of Antibodies Present in Human Sera Using a Novel Glycan Array
WO2006/068758
US-2008-0019968-A1

MDA04-108
Telomere Length as Measured on Cytological Specimens Predicts Presence of Cancer
US-2009-0162839-A1
WO2006/026714

MDA04-020
High Throughput Detection of Glutathione S-Transferase Polymorphic Alleles
7,083,923
WO/2002/008465
WO/2004/036179
US 2006-0194200 A1

MDA03-076
Loss of PTEN as a Novel Predictive Marker for Herceptin Resistance in ErbB2-Overexpressing Breast Cancers
US-2005-0287543-A1
WO2005/044091

MDA03-070
14-3-3Zeta Overexpression as a Poor Prognosis Factor, and a Therapeutic Target in Multiple Cancer Types
7,316,907
WO2005/055925
US 2008-0318231

MDA02-052
Real Time, Quantitative RT-PCR to AC133 to Detect and Quantify Circulating Endothelial Progenitor Cells in Human Peripheral Blood
7,252,976
WO2004/019864

MDA02-038
Fusion Proteins and Mutants for Detecting Gene Expression in vitro and in vivo
7,176,187
WO02/064747
US-2007-0161045-A1

MDA01-053
Identification of Tumor Markers and Potential Diagnostic and Therapeutic Targets for Human Gliomas By Gene Expression Profiling
7,341,552
WO03/078603

MDA00-053
Method for Detecting EGF-R Phosphorylation State in Hair Follicles and Buccal Mucosa
7,344,829
WO02/39121

MDA00-038
Cancer Prognostic and Diagnostic Assays
6,797,471
US-2006-0078885-A1
WO02/12563A2

MDA00-001
Haploid Protein Expression Test for Detection of Mutations
6,818,401
WO02/29107

MDA97-041
Synthetic Peptides from Human Papillomavirus (HPV) as Markers of Protective Immunity and as Reagents for Immunotherapy and Prophylaxis of HPV-Associated Cervical Cancer
7,410,758
WO2003/008649
US-2009-0053296-A1